Is Cell Point overvalued or undervalued?

As of 1 October 2025, the valuation grade for Cell Point has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently fairly valued, with a PE ratio of 33.91, an EV to EBITDA of 9.92, and a Price to Book Value of 0.46. These ratios suggest that while the company is not undervalued, it is also not excessively priced compared to its recent history.
In comparison to peers, Cell Point's PE ratio is significantly lower than Elitecon International's 422.46 and MMTC's 138.87, both of which are categorized as very expensive. Additionally, PTC India, which is considered very attractive, has a PE ratio of 8.07, further illustrating that Cell Point's valuation is reasonable within its competitive landscape. Notably, Cell Point has underperformed against the Sensex, with a year-to-date return of -32.15% compared to the Sensex's gain of 5.04%, which may reflect broader market sentiments impacting its valuation.